IP Library › Granted Patent US 7,129,390

Granted Patent B2

US 7,129,390 · App. 10/351,196 · Granted Oct 31, 2006

Poultry Derived Glycosylated Interferon Alpha 2b

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 7,129,390
App. No.: 10/351,196
Granted: Oct 31, 2006
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

This invention provides vectors and methods for the stable introduction of exogenous nucleic acid sequences into the genome of avians in order to express the exogenous sequences to alter the phenotype of the avians or to produce desired proteins. In particular, transgenic avians are produced which express exogenous sequences in their oviducts and which deposit exogenous proteins into their eggs. Avian eggs that contain exogenous proteins are encompassed by this invention. The instant invention further provides novel forms of interferon and erythropoietin which are efficiently expressed in the oviduct of transgenic avians and deposited into avian eggs.

Claims (83)

1. A human interferon-α 2b derived from a transgenic avian, wherein said interferon is O-glycosylated at Thr-106 with

Gal-NAcGal-, SA-Gal-NAcGal-, SA-Gal-NAcGal-, Gal-

NAcGlu-NAcGal-, Gal-Gal-NAcGal-, and Gal-Gal-

Gal

NAcGal-.

2. The interferon of claim 1 , wherein

Gal-NAcGal- is 20%, SA-Gal-NAcGal- is 29%, SA-Gal-

NAcGal- is 9%, Gal-NAcGlu-NAcGal- is 6%, Gal-Gal-

| |

SA Gal

NAcGal- is 7%, and Gal-Gal-NAcGal- is 12%.

3. The interferon of claim 1 , wherein said interferon is isolated.

4. The interferon of claim 1 , wherein said interferon is present in a hard shell egg.

5. The interferon of claim 4 , wherein said interferon is present in egg white of the hard shell egg.

6. A pharmaceutical composition comprising the interferon-α 2b, wherein said interferon is O-glycosylated at Thr-106 with

Gal-NAcGal-, SA-Gal-NAcGal-, SA-Gal-NAcGal-, Gal-

NAcGlu-NAcGal-, Gal-Gal-NAcGal-, and Gal-Gal-

Gal

NAcGal-.

said interferon is derived from a transgenic avian.

7. The pharmaceutical composition of claim 6 , wherein

Gal-NAcGal- is 20%, SA-Gal-NAcGal- is 29%, SA-Gal-

NAcGal- is 9%, Gal-NAcGlu-NAcGal- is 6%, Gal-Gal-

| |

SA Gal

NAcGal- is 7%, and Gal-Gal-NAcGal- is 12%.

8. The pharmaceutical composition of claim 6 , wherein the interferon is obtained from a hard shell egg.

9. The pharmaceutical composition of claim 8 , wherein the interferon is obtained from egg white of the hard shell egg.

10. A human interferon-α 2b derived from a transgenic avian comprising a poultry derived glycosylation pattern wherein the poultry derived glycosylation pattern is not the same as a human glycosylation pattern.

11. The interferon of claim 10 , wherein said interferon is O-glycosylated at Thr-106 with

Gal-NAcGal-, SA-Gal-NAcGal-, SA-Gal-NAcGal-, Gal-NAcGlu-NAcGal-,

| |

SA Gal

Gal-Gal-NAcGal-, and Gal-Gal-NAcGal-.

12. The interferon of claim 11 , wherein

Gal-NAcGal- is 20%, SA-Gal-NAcGal- is 29%, SA-Gal-NAcGal- is 9%,

Gal-NAcGlu-NAcGal- is 6%, SA

Gal

Gal-Gal-NAcGal- is 7%, and Gal-Gal-NAcGal- is 12%.

13. The interferon of claim 10 , wherein said interferon is present in a hard shell egg.

14. The interferon of claim 13 , wherein said interferon is present in egg white of the hard shell egg.

15. The interferon of claim 10 , wherein said interferon is isolated.

16. The interferon of claim 10 , wherein said interferon comprises SEQ ID NO: 30.

17. A pharmaceutical composition comprising a human interferon-α 2b with a poultry derived glycosylation pattern, wherein said interferon is derived from a transgenic avian and the poultry derived glycosylation pattern is not the same as a human glycosylation pattern.

18. The pharmaceutical composition of claim 17 , wherein said interferon is O-glycosylated at Thr-106 with

Gal-NAcGal-, SA-Gal-NAcGal-, SA-Gal-NAcGal-, Gal-NAcGlu-NAcGal-,

| |

SA Gal

Gal-Gal-NAcGal-, and Gal-Gal-NAcGal-.

19. The pharmaceutical composition of claim 18 , wherein

Gal-NAcGal- is 20%, SA-Gal-NAcGal- is 29%, SA-Gal-NAcGal- is 9%,

Gal-NAcGlu-NAcGal- is 6%, SA

Gal

Gal-Gal-NAcGal- is 7%, and Gal-Gal-NAcGal- is 12%.

20. The pharmaceutical composition of claim 17 , wherein said interferon is present in a hard shell egg.

21. The pharmaceutical composition of claim 20 , wherein said interferon is present in egg white of the hard shell egg.

22. The pharmaceutical composition of claim 20 , wherein said interferon comprises SEQ ID NO: 30.

Assignments (5)

CHANGE OF NAME Recorded Jan 30, 2009

From: AVIGENICS, INC.

To: SYNAGEVA BIOPHARMA CORP.

Reel/Frame 022177/0940 →

RELEASE OF SECURITY INTEREST Recorded Oct 16, 2007

From: FUQUA VENTURE PARTNERS I, LLC; KITTY HAWK CAPITAL LIMITED PARTNERSHIP, IV; TD LIGHTHOUSE CAPITAL FUND, L.P.; TD JAVELIN CAPITAL FUND II, L.P.; BAKER/TISCH INVESTORS LLC; BAKER BROS. INVESTMENTS, LLC; FOUR PARTNERS; FBB ASSOCIATES

To: AVIGENICS, INC.

Reel/Frame 019965/0285 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 13, 2004

From: SUTRAVE, PRAMOD

To: AVIGENICS, INC.

Reel/Frame 015062/0150 →

SECURITY AGREEMENT Recorded Jun 3, 2004

From: AVIGENICS, INC.

To: FUQUE VENTURE PARTNERS I, LLC; KITTY HAWK CAPITAL LIMITED PARTNERSHIP, IV; TD LIGHTHOUSE CAPITAL FUND, L.P.; TD JAVELIN CAPITAL FUND II, L.P.; BAKER/TISCH INVESTORS LLC; BAKER BROS. INVESTMENTS, LLC; FOUR PARTNERS; FBB ASSOCIATES

Reel/Frame 014683/0572 →

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 9, 2003

From: IVARIE, ROBERT D.; HARVEY, ALEX J..; MORRIS, JULIE A.; LIU, GUODONG; RAPP, JEFFREY C.

To: AVIGENICS, INC.; GEORGIA RESEARCH FOUNDATION, INC., UNIVERSITY OF

Reel/Frame 014060/0598 →